By Sheeba M. | March 20, 2026
Cannabis Rescheduling 2025: What Actually Changes for Investors
After years of legislative false starts, cannabis operators are finally facing a transformed federal landscape. Rescheduling to Schedule III isn’t just a symbolic victory — it’s a structural shift that rewrites the rules for how cannabis companies raise capital, manage operations, and get valued by investors.
What Actually Changes
The most immediate impact: Section 280E goes away. For cannabis companies that have been paying effective tax rates of 50-70% due to the IRS code’s prohibition on deductions, this is a massive cash flow boost.
Banking access is the second pillar. Cannabis businesses have been operating on a cash-only basis for years, which creates operational nightmares and security risks. FDIC-insured banks entering the sector means lower transaction costs, better security, and — importantly — the ability to build credit histories that unlock traditional lending.
What Doesn’t Change
Despite rescheduling, interstate commerce remains prohibited. Cannabis is still regulated like alcohol under the new framework — states control their own markets.
Social equity provisions aren’t going away either. Most states that issued licenses did so with social equity requirements — and courts have consistently upheld those provisions.
The Valuation Rethink
Cannabis investors have historically applied a discount to normalized earnings because of the tax burden and capital market restrictions. As those headwinds ease, that discount should compress.
Operators who can demonstrate positive EBITDA at the facility level will command premium valuations. Companies burning cash on cultivation that sells below wholesale prices will still struggle, tax benefits or not.
Positioning for the New Era
Look for operators with strong state-level market positions in mature markets like Colorado, Oregon, and California.
Curaleaf (CURLF) has the most extensive retail footprint among MSOs, with operations across 23 states.
Green Thumb Industries (GTI) has invested heavily in proprietary brands across consumer segments — vapes, edibles, concentrates.
Canopy Growth (CGC) continues to be a speculative play on the Constellation Brands’ deeper involvement.
Sources
- SEC Filings – Company financial data and regulatory filings
- Bloomberg Markets – Cannabis sector analysis and valuations
- MJBizDaily – Cannabis business news and regulatory updates
Related Articles
Track cannabis stocks with the Weedstock Real-Time Tracker